Beta Bionic, Inc. (BBNX)
| Market Cap | n/a |
| Revenue (ttm) | 53.03M |
| Net Income (ttm) | -55.50M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BBNX
Beta Bionic is a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration to utilize adaptive closed-loop algorithms to autonomously determine every insul... [Read more]
News
Beta Bionics Aims For IPO To Cover Heavy Losses
Beta Bionics is rapidly growing revenue but faces significant operating losses with no clear path to profitability in the near term. The firm is commercializing the FDA-cleared iLet Bionic Pancreas an...
Insulin delivery device maker Beta Bionics files for a $100 million IPO
Beta Bionics, which makes an automated insulin delivery system for type 1 diabetes, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Beta Bionics Files Registration Statement for Proposed Initial Public Offering
Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC....
Beta Bionics IPO Registration Document (S-1)
Beta Bionics has filed to go public with an IPO on the NASDAQ.